Trial reportThe Journal of infectious diseases2009
Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.
Trial report in The Journal of infectious diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00190151 (Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora
Who cites it
48 citing papers in PubMed.
- Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity.Antimicrobial agents and chemotherapy · 2019Trial
- Protection of the Human Gut Microbiome From Antibiotics.The Journal of infectious diseases · 2018Trial
- The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.Antimicrobial agents and chemotherapy · 2014Trial
- Ciprofloxacin beyond antibacterial therapy: pharmacological mechanisms, anticancer activity, and translational limitations.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Recent advances in piperazine derivatives as antibacterial agents: a comprehensive review (2020-2024).Molecular diversity · 2026Review
- Liver Cyst Infection Outcomes in Patients With ADPKD.Kidney international reports · 2026Article
- Article
- Utilization of Inhaled Antibiotics in Pediatric Non-Cystic Fibrosis Bronchiectasis: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2025Review
- Exceptions to the rule: When does resistance evolution not undermine antibiotic therapy in human bacterial infections?Evolution letters · 2024Article
- Emerging Microorganisms and Infectious Diseases: One Health Approach for Health Shared Vision.Genes · 2024Review
- Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?JAC-antimicrobial resistance · 2023Review
- The Drug-Specific Propensity Regarding the Acquisition of Fluoroquinolone Resistance inInfection and drug resistance · 2023Article
- Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation.CPT: pharmacometrics & systems pharmacology · 2022Article
- Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole UsingAntimicrobial agents and chemotherapy · 2021Article
- A Novel Non-Coding RNA CsiR Regulates the Ciprofloxacin Resistance inInternational journal of molecular sciences · 2021Article
- Influence of the H1 Antihistamine Mepyramine on the Antibacterial Effect of Florfenicol in Pigs.Veterinary sciences · 2021Article
- The Gut Microbiome as a Reservoir for Antimicrobial Resistance.The Journal of infectious diseases · 2021Review
- Piperazine based antimicrobial polymers: a review.RSC advances · 2021Review
- Antimicrobial properties of diethylamine NONOate, a nitric oxide donor, against Escherichia coli: a pilot study.The Journal of antibiotics · 2021Article
- Daptomycin treatment impacts resistance in off-target populations of vancomycin-resistant Enterococcus faecium.PLoS biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough optimization of the fluoroquinolone dosage increases the efficacy of this class of drugs against bacterial infections, its impact on the emergence of resistance in commensal bacteria is unknown.
methodsSix different 14-day dosages of oral ciprofloxacin were randomly assigned to 48 healthy volunteers. Individual pharmacokinetic and pharmacodynamic parameters combining antibiotic exposure in plasma, saliva, and stool specimens and ciprofloxacin minimum inhibitory concentrations (MICs) and mutant prevention concentrations against viridans group streptococci in the pharyngeal flora and Escherichia coli in the fecal flora were estimated. Their links with the emergence of resistance to nalidixic acid or ciprofloxacin in the fecal flora and to levofloxacin in the pharyngeal flora 7, 14, or 42 days after ciprofloxacin initiation were investigated.
resultsResistance emerged in the fecal and pharyngeal flora of 25% and 33% of the subjects, respectively, mainly when local concentrations of ciprofloxacin were less than the MIC. No variable that integrated pharmacokinetic data and pharmacodynamic parameters was found to differ significantly between the subjects in whom resistance emerged and those in whom it did not. Probabilities of the emergence of resistance were not significantly different across the different antibiotic dosages.
conclusionsSelection of resistant commensals during ciprofloxacin therapy is a frequent ecological side effect that is not preventable by dosage optimization. Trial registration. Clinical Trials.gov identifier: NCT00190151.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.